TY - JOUR
T1 - ALSUntangled #75
T2 - Portable neuromodulation stimulator therapy
AU - Officer, Laurel
AU - Armon, Carmel
AU - Barkhaus, Paul
AU - Beauchamp, Morgan
AU - Benatar, Michael
AU - Bertorini, Tulio
AU - Bowser, Robert
AU - Bromberg, Mark
AU - Brown, Andrew
AU - Carbunar, Olimpia Mihaela
AU - Carter, Gregory T.
AU - Crayle, Jesse
AU - Denson, Keelie
AU - Feldman, Eva
AU - Fullam, Timothy
AU - Heiman-Patterson, Terry
AU - Jackson, Carlayne
AU - Jhooty, Sartaj
AU - Levinson, Danelle
AU - Li, Xiaoyan
AU - Linares, Alexandra
AU - Mallon, Elise
AU - Mascias Cadavid, Javier
AU - Mcdermott, Christopher
AU - Mushannen, Tasnim
AU - Ostrow, Lyle
AU - Patel, Ronak
AU - Pattee, Gary
AU - Ratner, Dylan
AU - Sun, Yuyao
AU - Sladky, John
AU - Wicks, Paul
AU - Bedlack, Richard
N1 - Publisher Copyright:
© 2024 World Federation of Neurology on behalf of the Research Group on Motor Neuron Diseases.
PY - 2024
Y1 - 2024
N2 - Spurred by patient interest, ALSUntangled herein examines the potential of the Portable Neuromodulation Stimulator (PoNS™) in treating amyotrophic lateral sclerosis (ALS). The PoNS™ device, FDA-approved for the treatment of gait deficits in adult patients with multiple sclerosis, utilizes translingual neurostimulation to stimulate trigeminal and facial nerves via the tongue, aiming to induce neuroplastic changes. While there are early, promising data for PoNS treatment to improve gait and balance in multiple sclerosis, stroke, and traumatic brain injury, no pre-clinical or clinical studies have been performed in ALS. Although reasonably safe, high costs and prescription requirements will limit PoNS accessibility. At this time, due to the lack of ALS-relevant data, we cannot endorse the use of PoNS as an ALS treatment.
AB - Spurred by patient interest, ALSUntangled herein examines the potential of the Portable Neuromodulation Stimulator (PoNS™) in treating amyotrophic lateral sclerosis (ALS). The PoNS™ device, FDA-approved for the treatment of gait deficits in adult patients with multiple sclerosis, utilizes translingual neurostimulation to stimulate trigeminal and facial nerves via the tongue, aiming to induce neuroplastic changes. While there are early, promising data for PoNS treatment to improve gait and balance in multiple sclerosis, stroke, and traumatic brain injury, no pre-clinical or clinical studies have been performed in ALS. Although reasonably safe, high costs and prescription requirements will limit PoNS accessibility. At this time, due to the lack of ALS-relevant data, we cannot endorse the use of PoNS as an ALS treatment.
KW - Electrical stimulation
KW - PoNS™ Device
KW - neuromodulation
UR - http://www.scopus.com/inward/record.url?scp=85191295505&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85191295505&partnerID=8YFLogxK
U2 - 10.1080/21678421.2024.2346825
DO - 10.1080/21678421.2024.2346825
M3 - Article
C2 - 38666601
AN - SCOPUS:85191295505
SN - 2167-8421
VL - 25
SP - 648
EP - 652
JO - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
JF - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
IS - 5-6
ER -